Werewolf Therapeutics
HOWL

$2.73

1.77%

Market Cap: 119M

About: Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Employees: 46

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 10 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 5

96% more capital invested

Capital invested by funds: $107M [Q4 2023] → $209M (+$102M) [Q1 2024]

49% more funds holding

Funds holding: 41 [Q4 2023] → 61 (+20) [Q1 2024]

25% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 12

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

1.0% less ownership

Funds ownership: 76.46% [Q4 2023] → 75.46% (-1.0%) [Q1 2024]

86% less call options, than puts

Call options by funds: $32K | Put options by funds: $227K

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$12

340%

upside

Avg. target

$13.80

405%

upside

High target

$15

449%

upside

10 analyst ratings

10 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Andres Maldonado	449%upside $15	Buy Reiterated	2 Jul 2024
JMP Securities Reni Benjamin	340%upside $12	Market Outperform Reiterated	26 Jun 2024
HC Wainwright & Co. Andres Maldonado	449%upside $15	Buy Reiterated	26 Jun 2024
JMP Securities Reni Benjamin	340%upside $12	Market Outperform Reiterated	4 Jun 2024
HC Wainwright & Co. Andres Maldonado	449%upside $15	Buy Reiterated	3 Jun 2024

See Analyst Rankings

Financial journalist opinion

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Werewolf Therapeutics, Inc. is an early-stage biotech focusing on cytokine therapy for cancer treatment. The Pipeline update includes positive results for WTX-124 in clinical trials and promising data for WTX-330. Financially, the company has a decent cash position for now, but may need to address cash burn rate in the near future.

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data for rhIL-12 -

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy -

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 1:00 PM ET on June 6 at the Jefferies Global Healthcare Conference, taking place June 4-6, 2024, in New York City, New York.

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers -

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

— Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors at ASCO —

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

First Data Demonstrating Application of PREDATOR™ Platform in Immune-Mediated Diseases WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced a poster presenting preclinical data characterizing conditionally-activated IL-10 INDUKINE molecules for the treatment of colitis in animal models, a novel approach leveraging its PREDATOR™ protein engineering platform, at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois.

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Zacks Investment Research

All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy

Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

WTX-518, a conditionally activated IL-18 INDUKINE TM molecule that resists suppression by IL-18BP, led to complete tumor regressions in preclinical models

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

See News Rankings